Fideuram Asset Management Ireland dac Purchases New Stake in Pfizer Inc. $PFE

Posted by Stanley Muller on May 30th, 2026

Fideuram Asset Management Ireland dac purchased a new stake in Pfizer Inc. (NYSE:PFE – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund purchased 80,157 shares of the biopharmaceutical company’s stock, valued at approximately $2,111,000.

Several other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after buying an additional 7,031,162 shares during the period. State Street Corp raised its holdings in Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after buying an additional 2,786,098 shares during the period. Geode Capital Management LLC raised its holdings in Pfizer by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after buying an additional 1,184,728 shares during the period. Northern Trust Corp raised its holdings in Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after buying an additional 869,175 shares during the period. Finally, Fisher Asset Management LLC raised its holdings in Pfizer by 5.4% in the fourth quarter. Fisher Asset Management LLC now owns 51,952,106 shares of the biopharmaceutical company’s stock valued at $1,293,607,000 after buying an additional 2,664,052 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.2%

PFE opened at $26.18 on Friday. The firm has a market capitalization of $149.23 billion, a P/E ratio of 19.99 and a beta of 0.35. The firm’s 50 day moving average is $26.77 and its 200-day moving average is $26.28. Pfizer Inc. has a 52-week low of $23.06 and a 52-week high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s payout ratio is 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer announced a major global oncology collaboration with Innovent Biologics worth up to $10.5 billion. The deal gives Pfizer access to 12 early-stage cancer programs and expands its cancer pipeline, which investors may see as a long-term growth driver. Article Title
Positive Sentiment: Pfizer reported seven-year follow-up data from its LORBRENA CROWN trial, showing the longest progression-free survival reported to date in advanced ALK-positive non-small cell lung cancer. Strong late-stage clinical evidence can support the drug’s commercial outlook and reinforce Pfizer’s oncology franchise. Article Title
Positive Sentiment: Several reports highlighted progress in Pfizer’s clinical pipeline, including updates tied to lung cancer and obesity programs. Investors often reward pipeline milestones because they can improve future revenue potential and diversify growth beyond existing products. Article Title
Neutral Sentiment: Commentary on insider activity suggested Pfizer insiders are not buying shares aggressively at current levels, but the article framed that as a lack of negative signal rather than a warning sign. This is more of a valuation/sentiment note than a direct catalyst. Article Title
Neutral Sentiment: Additional items referenced early-stage trial updates and a real-world lung cancer study on dacomitinib. These are constructive for the pipeline, but they are still early and likely less material than the Innovent deal or the LORBRENA data. Article Title

Analyst Upgrades and Downgrades

PFE has been the topic of several research reports. BMO Capital Markets restated an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. Wolfe Research reiterated an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. CICC Research initiated coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. Finally, HSBC lifted their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $28.82.

Read Our Latest Stock Analysis on PFE

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.